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Despite advances in the interventional treatment of coronary disease, diabetics still have
double the case fatality rate as nondiabetics. The purpose of this analysis from the
Radiation in Europe With Novoste (RENO) registry was to assess the clinical and angio-
graphic 6-month outcome of diabetic patients in comparison to nondiabetic patients
after localized -radiation. A total of 1,098 patients (83.8% with in-stent restenosis)
treated with the Novoste Beta-Cath system in Europe were enrolled in the RENO registry.
Diabetes was, irrespective of the type of lesion treated, no significant risk factor for major
adverse cardiac events or target vessel revascularization. Individuals with diabetes (n 
256) and without diabetes (n  833) displayed no significant differences concerning
clinical or angiographic endpoints. Vascular brachytherapy appears to be the first tech-
nique to even out the increased risk of diabetic patients undergoing percutaneous
coronary interventions in the routine clinical setting. Thus, intracoronary brachytherapy
represents a promising treatment option for diabetic patients. Catheter Cardiovasc Interv
2004;61:173–178. © 2004 Wiley-Liss, Inc.
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INTRODUCTION
Cardiovascular disease is the major cause of morbidity
and mortality in patients with diabetes. Diabetic individ-
uals have a two- to fourfold risk for vascular disease than
nondiabetics. Diabetes mellitus has a negative impact on
mortality and morbidity following catheter-based coro-
nary procedures as well as coronary artery bypass sur-
gery [1,2]. Recent advances in the treatment of coronary
disease have improved survival for diabetics and nondia-
betics, but diabetics still have double the case fatality rate
as nondiabetics [3]. Determinants such as high athero-
sclerosis burden, complex lesion morphology, small tar-
get vessel size, and a higher rate of multivessel disease
may predispose to the observed excess restenosis rates,
which remain the major limitation of catheter-based cor-
onary interventions among patients with diabetes melli-
tus, irrespective of whether the treatment is performed in
native vessels [4–8], saphenous vein grafts [9], or in-
stent restenosis [10–12]. Particular for the treatment of
in-stent restenosis, intracoronary brachytherapy is cur-
rently the only effective tool to reduce the excess reste-
nosis rates of 19–83% [13] significantly by 40–60%
[14–18]. Interestingly, recent subanalyses from clinical
brachytherapy trials demonstrated for the first time that
diabetics appear to profit at least to the same extent from
percutaneous interventions as compared to nondiabetic
patients [19]. This finding was independent of the type of
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radiation and could be observed after - as well as after
-radiation [20,21]. It is thus tempting to speculate on
whether such a favorable outcome of diabetic patients
following catheter-based coronary procedures can be ob-
served also in the clinical routine setting, besides the
potential selection bias of controlled clinical trial popu-
lations. The purpose of this analysis was to assess the
clinical and angiographic outcome 6 months after local-
ized -radiation (90strontium/yttrium) in diabetic patients
with predominantly long diffuse in-stent restenosis from
the Radiation in Europe With Novoste (RENO) registry.
RENO enrolled the first 1,100 patients treated with the
Novoste Beta-Cath system in Europe and therefore per-
fectly mirrored the clinical routine situation during the
enrollment period from June 1999 to September 2000. As
the reduction of restenosis rate and target vessel revas-
cularization (TVR) was well comparable to those of
randomized brachytherapy trials, the RENO registry has
proven that these results can be successfully achieved
also in the routine clinical setting [22].
MATERIALS AND METHODS
The RENO registry was a postmarket prospective sur-
veillance study enrolling 1,098 consecutive patients at 46
European centers treated with conventional interven-
tional therapies followed by localized -radiation using
the Novoste Beta-Cath system. Patients with de novo or
restenotic lesions and objective evidence of ischemia
were treated with approved interventional procedures
(balloon angioplasty, percutaneous rotational atherec-
tomy (PTRA), excimer laser coronary angioplasty
(ELCA), directional coronary atherectomy (DCA), and
stenting) followed by 90strontium radiation treatment
(Novoste Beta-Cath system). Patient enrollment occurred
from 1 June 1999 to 27 September 2000.
Detailed proceedings have been published elsewhere
[22]. In brief, baseline and clinical data were collected on
standardized case report forms at the clinical sites. Clin-
ical follow-up was mandated at 1 and 6 months. Angio-
graphic follow-up at 6 months was not mandated, how-
ever, but is available on 72.4% of the patients.
The primary endpoint of the study was procedural
success without occurrence of major adverse cardiac
events (including death, myocardial infarction, revascu-
larization of the target vessel) after 6 months. After
successful completion of the interventional procedure,
the angioplasty catheter was withdrawn. Next, the Beta-
Rail delivery catheter was positioned and radiation ther-
apy was performed as described [22] with a recom-
mended dose prescription of 18.4 to 23 Gy at 2 mm from
the radiation source depending on the vessel diameter.
All RENO patients received a combination treatment
of aspirin (100 mg) and clopidogrel/ticlopidine. The du-
ration of treatment was, however, determined by the
respective operator’s routine use of this combination.
From the steering committee, a 6-month combination
treatment was recommended. Based on the results, 70%
of patients received the combination treatment for longer
than 6 months. The remaining patients received a com-
bination treatment for 3–6 months.
Baseline demographic and clinical variables were de-
scriptively summarized. Diabetic and nondiabetic pa-
tients were assessed for comparability at baseline and
follow-up using chi-square tests or Fisher’s exact test for
nominal variables and exact Mann-Whitney U-tests for
continuous variables. Odds ratios and 95% confidence
intervals for diabetes vs. nondiabetes were calculated for
the outcome variables 6-month MACE and TVR or
6-month binary restenosis using logistic regression mod-
els, either adjusted or unadjusted for 17 baseline vari-
ables (age, gender, unstable angina, bypass graft, in-stent
restenosis, chronic total occlusion, new stent placement,
cutting balloon used, final residual stenosis, reference
diameter, lesion length, maximum balloon size, applied
dose, total radiated length, ratio of lesion length to radi-
ated length, pullback procedure used, and geographic
miss). All statistical analyses were performed using
SPSS 10.0.7 by SPSS. A P value of  0.05 is regarded
as statistically significant.
RESULTS
Baseline demographic data are presented in Table I.
There were more female patients and less current smok-
ers in the diabetic group. Diabetics were slightly older,
and there were more diabetic patients with multivessel
disease.
Angiographic and interventional parameters are dis-
played in Table II. Lesion characteristics and procedural
data were not significantly different between the groups.
The pattern of in-stent restenosis categorized as focal, at
the stent ends, or diffuse was similar between diabetic
(18.3% vs. 3.3% vs. 78.4%) and nondiabetic patients
(16.5% vs. 5.3% vs. 78.2%, respectively; P  0.4). The
applied dose was slightly lower in the diabetic patients,
and a regression model with mean radiation dose as
response variable and diabetes and vessel diameter as
regressors reveals that this difference persists after ad-
justment for vessel diameter. The odds ratio for MACE
was 0.94/Gy in diabetic and nondiabetic patients.
There were no differences between the groups regard-
ing technical success rates and in-hospital events. The
6-month clinical and angiographic follow-up including
the in-hospital events are displayed in Table III. With
respect to the clinical and angiographic outcome after 6
months, no significant differences could be observed
between the groups (Table III and Fig. 1). Odds ratios of
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6-month MACE for diabetes were 1.14 (95% CI 
0.8–1.62) unadjusted and 1.30 (95% CI  0.87–1.93)
after adjustment for the baseline variables. For TVR or
restenosis, odds ratios were 0.93 (95% CI  0.65–1.34)
unadjusted and 0.99 (95% CI  0.68–1.45) after adjust-
ment. There were no significant interactions between
diabetes and any of the baseline variables included.
After stratification for the type of the treated lesion,
there were also no significant differences between the
groups (Table I and Fig. 2), although diabetic patients
with de novo stenosis appeared to have somewhat higher
rates of binary restenosis, TVR, and target vessel throm-
bosis. The odds ratios related to diabetes, stratified for the
type of lesion treated, are displayed in Figure 3.
DISCUSSION
It is not yet clear why diabetic patients have such an
unfavorable outcome following catheter-based coronary
procedures. Van Belle et al. [23] concluded from their
data that restenosis, especially in its occlusive form, is a
major determinant of long-term mortality in diabetic
patients after coronary balloon angioplasty due to a sig-
nificant decrease in ejection fraction [24]. Serial IVUS
analysis showed that the main reason for increased re-
stenosis in diabetes mellitus was exaggerated intimal
hyperplasia in both stented and nonstented lesions [25].
Histopathological analyses from coronary specimens
from patients with diabetes mellitus yielded a reduced
TABLE I. Demographic and Clinical Data
Parameter
All In-stent restenosis De novo lesions
Diabetes No diabetes Diabetes No diabetes Diabetes No diabetes
n 256 833 209 657 35 143
Sex (male) 69.1a 78.8 70.3a 77.8 68.6 80.4
Age (years) 63.8  9.8a 61.5  10.2 64.1  10.0 61.6  10.5 60.9  9.1 61.2  9.5
Prior MI 35.2 36.3 36.7 38.2 26.5 27.5
Multivessel disease 62.1a 46.3 61.7a 45.1 62.9 50.3
one vessel treated 4.3 6.6 3.8 5.2 8.6 11.9
Unstable angina 30.5 25.7 28.7 23.5 32.4 32.5
Hyperlipidemia 81.5 76.6 81.6 79.3 80.0 62.9
Current smoking 12.2a 17.0 11.0 14.7 23.5 26.1
aP  0.05 vs. no diabetes.
TABLE II. Angiographic Data
Parameter
All In-stent restenosis De novo lesions
Diabetes No diabetes Diabetes No diabetes Diabetes No diabetes
Treated vessels 267 897 217 694 38 168
Lesion length (mm) 18.7  11.4 19.1  11.9 18.9  11.7 19.7  12.6 18.0  11.0 17.4  9.3
Reference diameter (mm) 3.2  0.5 3.2  0.5 3.2  0.4 3.2  0.5 3.1  0.5 3.2  0.5
In-stent restenosis 80.8 76.7 100.0 100.0 0.0 0.0
Bypass 7.9 5.4 7.8 5.1 5.3 6.0
Cutting balloon 17.6 14.0 20.7 17.3 0.0 1.2
New stent 26.2 30.6 15.2 19.3 81.6 75.6
Technical success 96.9 95.5 96.7 95.2 97.3 96.4
Geographic miss 6.1 6.2 5.1 6.4 13.2 6.0
Mean dose (Gy) 18.4  3.1a 19.0  3.2 18.6  3.2a 19.2  3.1 17.4  2.9a 18.4  3.3
aP  0.05 vs. no diabetes.
TABLE III. Six-Month Clinical and Angiographic Follow-Up Including In-Hospital Events
Parameter
All In-stent restenosis De novo lesions
Diabetes No diabetes Diabetes No diabetes Diabetes No diabetes
n 256 833 209 657 35 143
Death 7 (2.7) 14 (1.7) 6 (2.9) 11 (1.7) 0 (0.0) 3 (2.1)
Cardiac 5 (2.0) 7 (0.8) 5 (2.4) 5 (0.8) 0 (0.0) 2 (1.4)
MI 10 (3.9) 18 (2.2) 7 (3.3) 14 (2.1) 2 (5.7) 3 (2.1)
Q-wave 4 (1.6) 7 (0.8) 3 (1.4) 5 (0.8) 1 (2.9) 1 (0.7)
Death or MI 15 (5.9) 30 (3.6) 11 (5.3) 23 (3.2) 2 (5.7) 6 (4.2)
TVR 44 (17.2) 136 (16.1) 31 (14.8) 102 (15.5) 10 (28.6) 28 (19.6)
MACEs 52 (20.3) 152 (18.2) 37 (17.7) 115 (17.5) 11 (31.4) 33 (23.1)
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intimal hypercellular tissue content in restenotic tissue
from these patients, while collagen-rich sclerotic content
was increased [26]. The authors concluded that these
results suggest an accelerated fibrotic rather than a pro-
liferative response in diabetic lesions from patients with
restenosis after PTCA. On the other hand, Faries et al.
[27] demonstrated that diabetic vascular smooth muscle
cells (VSMCs) exhibit significantly increased rates of
proliferation, adhesion, and migration as well as abnor-
mal cell culture morphology suggestive of abnormal con-
tact inhibition.
For the long term, diabetic patients have remained one
of the most challenging tasks in interventional cardiol-
ogy. The case fatality and restenosis rates were far worse
in diabetic than in nondiabetic patients, irrespective of
the treatment modality or the nature of the treated lesion
[4–13].
Recent results from controlled intracoronary brachy-
therapy trials indicated for the first time that diabetic
patients may profit significantly from a catheter-based
interventional technique with long-term result compara-
ble to nondiabetic patients. In the Scripps Coronary Ra-
diation to Inhibit Proliferation Poststenting (SCRIPPS)
trial, Teirstein et al. [19] showed that in the treatment
group, late loss was particularly low in patients with
diabetes, a vessel diameter  3.0 mm, and in-stent re-
stenosis. The authors concluded that in this study, patient
characteristics associated with a more aggressive prolif-
erative response to injury appeared to confer an enhanced
response to radiotherapy. Similar results were published
also for -radiation [20,28], and even more surprising
were the results from the GAMMA-I trial, which yielded
after brachytherapy treatment a reduction in binary re-
stenosis of 16% in the nondiabetic patients and of even
40% in the diabetic patients [21].
These findings are clearly supported by the data from
the RENO registry reported here, which represents the
largest single series of diabetic patients treated with
brachytherapy to date. Common risk factors for resteno-
Fig. 1. Clinical and angiographic 6-month follow-up, all pa-
tients. BR, binary restenosis (> 50% diameter restenosis); TOC,
total occlusion of target vessel in angiography; TVT, surrogate
composite endpoint of target vessel thrombosis (target vessel-
related cardiac death, MI after 30 days, total target vessel
occlusion on angiography).
Fig. 2. Clinical and angiographic 6-month follow-up, stratified
for initial lesion type. ISR, in-stent-restenosis.
Fig. 3. Odds ratios for diabetes for (A) MACE and (B) TVR/
restenosis.
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sis such as lesion length, reference vessel diameter, and
type of target lesion were comparable between the
groups. Although the diabetic group consisted of signif-
icantly more patients with multivessel disease, there were
no statistically significant differences regarding the clin-
ical and angiographic outcome between the groups after
6 months. Diabetes was no significant risk factor for
MACE and TVR or angiographic restenosis in a multi-
variate analysis.
Subanalyses of the patients with in-stent restenosis and
those with de novo lesions also yielded no significant
differences between the groups, although diabetic pa-
tients with de novo stenosis appeared to have somewhat
higher rates of binary restenosis, TVR, total occlusions,
and target vessel thrombosis. On the other hand, these
patients received also the lowest mean radiation dose,
had the highest rate of geographic miss (inadequate ra-
diation of the interventional injury length), and the high-
est number of new implanted stents. These facts, and the
small number of patients in the RENO de novo group,
indicate that the results of this subanalysis should be
interpreted with caution.
In conclusion, the above findings indicate, with respect
to the expected high case fatality in diabetic patients, that
intracoronary brachytherapy represents a promising
treatment option for diabetic patients. Vascular brachy-
therapy appears to be the first percutaneous interven-
tional technique from which diabetic patients profit to at
least the same extent that nondiabetic individuals do.
It appears reasonable to assume that the exaggerated
intimal hyperplasia is counteracted by the antiprolifera-
tory properties of intracoronary irradiation. Thus, it may
be suggested that other antiproliferative therapies can be
equally effective to even out the increased risk of diabetic
patients undergoing percutaneous coronary interventions.
Study Limitations
The data entered into this analysis were taken from a
large prospective multicenter registry. This registry was
not designed to aim at differences between diabetics and
nondiabetics undergoing intracoronary radiation. Thus,
although our findings confirm findings from prospective
studies in clinical practice, the power of the study, espe-
cially regarding the subgroup analysis, is not sufficient to
show equivalence between the groups.
Another limitation is that due to the design of the
RENO registry, there is no information on the type of
diabetes or the antidiabetic treatment of the included
patients available. Also, no information is available on
the number or kind of previous treatments at the target
lesion.
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